272 related articles for article (PubMed ID: 29982109)
1. Teeth loss after teriflunomide treatment: Casual or causal? A short case series.
Vacchiano V; Frattaruolo N; Mancinelli L; Foschi M; Carotenuto A; Scandellari C; Piattelli M; Brescia Morra V; Lugaresi A
Mult Scler Relat Disord; 2018 Aug; 24():120-122. PubMed ID: 29982109
[TBL] [Abstract][Full Text] [Related]
2. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
3. ▼Teriflunomide for multiple sclerosis.
Drug Ther Bull; 2014 Jul; 52(7):81-4. PubMed ID: 25012149
[TBL] [Abstract][Full Text] [Related]
4. Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis.
Papadopoulou A; Kappos L; Sprenger T
Expert Opin Drug Saf; 2015 May; 14(5):749-59. PubMed ID: 25687236
[TBL] [Abstract][Full Text] [Related]
5. A case of lymphoma in a patient on teriflunomide treatment for relapsing multiple sclerosis.
Landais A; Alhendi R; Gouverneur A; Teron-Aboud B
Mult Scler Relat Disord; 2017 Oct; 17():92-94. PubMed ID: 29055483
[TBL] [Abstract][Full Text] [Related]
6. Rebound syndrome after teriflunomide cessation in a patient with multiple sclerosis.
Yamout BI; Said M; Hannoun S; Zeineddine M; Massouh J; Khoury SJ
J Neurol Sci; 2017 Sep; 380():79-81. PubMed ID: 28870594
[TBL] [Abstract][Full Text] [Related]
7. Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.
Tilly G; Cadoux M; Garcia A; Morille J; Wiertlewski S; Pecqueur C; Brouard S; Laplaud D; Degauque N
Front Immunol; 2021; 12():730342. PubMed ID: 34721394
[TBL] [Abstract][Full Text] [Related]
8. Teriflunomide: a novel oral treatment for relapsing multiple sclerosis.
Sartori A; Carle D; Freedman MS
Expert Opin Pharmacother; 2014 May; 15(7):1019-27. PubMed ID: 24742277
[TBL] [Abstract][Full Text] [Related]
9. Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report.
Ferreira CM; Vasconcelos-Pereira EF; Oliveira VM; Salgado PR; Domingos JA; Monreal MTFD; Guerra-Shinohara EM; Gubert VT
Medicine (Baltimore); 2021 Dec; 100(51):e28246. PubMed ID: 34941096
[TBL] [Abstract][Full Text] [Related]
10. Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis.
Chan A; de Seze J; Comabella M
CNS Drugs; 2016 Jan; 30(1):41-51. PubMed ID: 26758290
[TBL] [Abstract][Full Text] [Related]
11. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
Comi G; Freedman MS; Kappos L; Olsson TP; Miller AE; Wolinsky JS; O'Connor PW; Benamor M; Dukovic D; Truffinet P; Leist TP
Mult Scler Relat Disord; 2016 Jan; 5():97-104. PubMed ID: 26856952
[TBL] [Abstract][Full Text] [Related]
12. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
Guarnera C; Bramanti P; Mazzon E
Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
[TBL] [Abstract][Full Text] [Related]
13. "Nail loss after teriflunomide treatment: A new potential adverse event".
Mancinelli L; Amerio P; di Ioia M; Di Tommaso V; De Luca G; Onofrj M; Lugaresi A
Mult Scler Relat Disord; 2017 Nov; 18():170-172. PubMed ID: 29141803
[TBL] [Abstract][Full Text] [Related]
14. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.
Miller AE
Clin Ther; 2015 Oct; 37(10):2366-80. PubMed ID: 26365096
[TBL] [Abstract][Full Text] [Related]
15. Teriflunomide for multiple sclerosis in real-world setting.
Elkjaer ML; Molnar T; Illes Z
Acta Neurol Scand; 2017 Nov; 136(5):447-453. PubMed ID: 28321835
[TBL] [Abstract][Full Text] [Related]
16. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW;
Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D
Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698
[TBL] [Abstract][Full Text] [Related]
18. Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.
Miller AE
Expert Rev Clin Immunol; 2015 Feb; 11(2):181-94. PubMed ID: 25511008
[TBL] [Abstract][Full Text] [Related]
19. Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.
Brunetti L; Wagner ML; Maroney M; Ryan M
Ann Pharmacother; 2013 Sep; 47(9):1153-60. PubMed ID: 24259730
[TBL] [Abstract][Full Text] [Related]
20. Digestive side-effects with teriflunomide: Thoughts on lactose.
Lebrun C; Bertagna M; Bresch S; Cohen M
Rev Neurol (Paris); 2018 Dec; 174(10):722-725. PubMed ID: 30409479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
